BioNTech’s (BNTX) “Buy” Rating Reiterated at The Goldman Sachs Group

The Goldman Sachs Group reaffirmed their buy rating on shares of BioNTech (NASDAQ:BNTX) in a research note released on Wednesday morning,MarketScreener reports.

Several other equities analysts also recently weighed in on BNTX. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research report on Friday, January 9th. UBS Group upgraded BioNTech to a “hold” rating in a research report on Thursday, December 4th. HC Wainwright reaffirmed a “buy” rating and issued a $140.00 price objective on shares of BioNTech in a research note on Thursday, December 11th. Morgan Stanley lowered their price objective on BioNTech from $134.00 to $125.00 and set an “overweight” rating on the stock in a research report on Tuesday. Finally, Bank of America reiterated a “buy” rating and set a $128.00 price objective on shares of BioNTech in a research note on Tuesday. Twelve analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $133.73.

BioNTech Trading Up 1.2%

Shares of BNTX stock opened at $91.19 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.02. The company has a market cap of $20.53 billion, a price-to-earnings ratio of -17.40 and a beta of 1.51. BioNTech has a 1 year low of $79.52 and a 1 year high of $124.00. The firm has a fifty day moving average price of $106.43 and a 200-day moving average price of $102.56.

Institutional Investors Weigh In On BioNTech

Institutional investors and hedge funds have recently bought and sold shares of the business. Dodge & Cox lifted its position in shares of BioNTech by 315.7% in the third quarter. Dodge & Cox now owns 3,647,091 shares of the company’s stock valued at $359,676,000 after acquiring an additional 2,769,654 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after acquiring an additional 474,796 shares during the period. GSK plc purchased a new stake in shares of BioNTech during the fourth quarter worth about $84,711,000. Franklin Resources Inc. raised its stake in BioNTech by 76.8% during the 2nd quarter. Franklin Resources Inc. now owns 751,998 shares of the company’s stock valued at $80,065,000 after purchasing an additional 326,556 shares during the period. Finally, Invesco Ltd. raised its stake in BioNTech by 5.6% during the 2nd quarter. Invesco Ltd. now owns 681,100 shares of the company’s stock valued at $72,517,000 after purchasing an additional 35,958 shares during the period. 15.52% of the stock is owned by institutional investors.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.